FDA Action Alert: Aquestive, Eton and MesoblastAdrenal Glands, Adrenal Insufficiency, Business, Clinical Trials, Congenital Adrenal Hyperplasia (CAH), Epilepsy, FDA/Regulatory, Glands, New Drug Application (NDA), Oncologic Drugs Advisory Committee (ODAC), PDUFA, Pediatric, Quarterly results, R&D, Seizure ClustersThe U.S. Food and Drug Administration is wrapping up the month of September with a few PDUFA dates, including an approval review of Aquestive’s Libervant for the management of seizure clusters in epilepsy. Read more September 28, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/09/FDA-Action-Alert-Aquestive-Eton-and-Mesoblast-BioSpace-9-28-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-09-28 11:54:172020-09-28 12:50:23FDA Action Alert: Aquestive, Eton and Mesoblast